Arch Virol

1. LATEEF MO, Aransi AT, Nathaniel D
   Genome diversity and evolutionary understanding of Lassa virus: a holistic approach highlighting a potential target for cross-lineage vaccine development.
   Arch Virol. 2025;171:7.
   

   >> Share

   
   

   
   BMJ

2. LANG K
   Is the UK government "withholding data linking covid vaccines to excess deaths"?
   BMJ. 2025;391:r2499.
   

   >> Share

   
   
3. WISE J
   HPV vaccine safe and reduces risk of cervical cancer, anti-misinformation review finds.
   BMJ. 2025;391:r2479.
   

   >> Share

   
   
4. TANNE JH
   Whooping cough surges in US as vaccination rates fall.
   BMJ. 2025;391:r2485.
   

   >> Share

   
   

   
   Infect Immun

5. AVINA SL, Pawar S, Kadam RN, Rivera A, et al
   Mannoprotein Cig1 contributes to the immunogenicity of a heat-killed F-box protein Fbp1 Cryptococcus neoformans vaccine model.
   Infect Immun. 2025 Nov 28:e0035525. doi: 10.1128/iai.00355.
   

   >> Share

   
   
6. KAWASHIMA S, Takahashi K, Yanagisawa D, Irikura C, et al
   Immunogenicity and plasmid delivery pathways of non-invasive Lactococcus lactis-vectored mucosal DNA vaccination.
   Infect Immun. 2025 Nov 28:e0046025. doi: 10.1128/iai.00460.
   

   >> Share

   
   

   
   J Infect Dis

7. WINOKUR P, Hegmann TE, El Sahly HM, Anderson EJ, et al
   A Phase 1 Double-Blinded Trial to Evaluate Safety, Immunogenicity, and Dosing of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults.
   J Infect Dis. 2025 Nov 28:jiaf571. doi: 10.1093.
   

   >> Share

   
   
8. ALAIMO C, Karaky N, Lawrence R, Bownes E, et al
   Safety and immunogenicity of a Klebsiella pneumoniae tetravalent bioconjugate vaccine (Kleb4V) administered to healthy adults: A first time in human phase I/II randomised and controlled study.
   J Infect Dis. 2025 Nov 25:jiaf600. doi: 10.1093.
   

   >> Share

   
   
9. CHAPPELL KJ, Mordant FL, Amarilla AA, Modhiran N, et al
   Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trial.
   J Infect Dis. 2025 Nov 25:jiaf568. doi: 10.1093.
   

   >> Share

   
   
10. CLARK ES, Garrido G, Levay A, Schrand B, et al
    Vaccination against pathogens targeting cell-derived cryptic antigens.
    J Infect Dis. 2025 Nov 24:jiaf593. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

11. WANG W, Du P, Zhao Y, Liang Y, et al
    Biomimetic nanovaccines with self-adjuvant effects induced broad-spectrum neutralizing antibodies against SARS-CoV-2 infection in rodents.
    J Virol. 2025 Oct 10:e0031525. doi: 10.1128/jvi.00315.
    

    >> Share

    
    
12. LEI H, Xiao B, Lin X, Liang Z, et al
    Chronology of H3N2 human influenza virus surface glycoprotein adaptation from 1968 to 2019 reveals a surge of adaptation between 1997 and 2002.
    J Virol. 2025 Oct 31:e0132925. doi: 10.1128/jvi.01329.
    

    >> Share

    
    
13. ZHANG D, Yuan Y, Hu G, Xie Y, et al
    Engineering a TGEV S-trimer chimera with PEDV D0-NTD generates potent neutralizing antibodies against both viruses.
    J Virol. 2025 Oct 31:e0145225. doi: 10.1128/jvi.01452.
    

    >> Share

    
    
14. LI Q, Mishra H, Kain KC, Wang R, et al
    The hidden threats posed by Japanese encephalitis virus genotype V.
    J Virol. 2025;99:e0164425.
    

    >> Share

    
    
15. SAUL S, Dahal B, Luongo C, Liu X, et al
    Intranasal bovine/human parainfluenza virus 3 vaccine candidates expressing human metapneumovirus wild-type or pre-fusion F protein elicit protective immunity against human metapneumovirus in hamsters.
    J Virol. 2025 Nov 25:e0114525. doi: 10.1128/jvi.01145.
    

    >> Share

    
    

    
    Nat Med

16. O'LEARY K
    A much-needed vaccine for Nipah virus.
    Nat Med. 2025 Nov 26. doi: 10.1038/d41591-025-00068.
    

    >> Share

    
    
17. BARETTI M, Kirk AM, Ladle BH, Kamdar Z, et al
    A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.
    Nat Med. 2025 Nov 24. doi: 10.1038/s41591-025-03995.
    

    >> Share

    
    

    
    PLoS Comput Biol

18. XU S, Hudson A, Janes HE, Tomaras GD, et al
    Candidate correlates of protection in the HVTN505 HIV-1 vaccine efficacy trial identified by positive-unlabeled learning.
    PLoS Comput Biol. 2025;21:e1013705.
    

    >> Share

    
    

    
    PLoS One

19. FISHER SS, Lindaas A, Muthuri SG, Lloyd PC, et al
    Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.
    PLoS One. 2025;20:e0333704.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

20. JAMIESON KH, Gibson LA, Jamieson PE, Patterson S Jr, et al
    Using a mental model approach to undercut the effects of exposure to mRNA vaccination misconceptions: Two randomized trials.
    Proc Natl Acad Sci U S A. 2025;122:e2517067122.
    

    >> Share

    
    
21. CAPUCETTI A, Falivene J, Pizzichetti C, Latino I, et al
    Tattoo ink induces inflammation in the draining lymph node and alters the immune response to vaccination.
    Proc Natl Acad Sci U S A. 2025;122:e2510392122.
    

    >> Share

    
    

    
    Vaccine

22. CHAU SL, Hung IFN, Luk TT, Chan SSC, et al
    The impacts of long COVID and booster doses of post-infection vaccination among hospital-discharged COVID-19 survivors in Hong Kong: A retrospective observational study.
    Vaccine. 2025;70:128022.
    

    >> Share

    
    
23. CHAZARIN B, Bhat AS, Sundararaman N, Liu Y, et al
    Longitudinal proteomic and autoantibody signatures after mRNA vaccination in healthy individuals.
    Vaccine. 2025;70:127888.
    

    >> Share

    
    
24. DOULOU K, Bacopoulou F, Michos A, Tsolakidis A, et al
    HPV vaccination coverage among children and adolescents in Greece using national prescription data.
    Vaccine. 2025;70:128026.
    

    >> Share

    
    
25. VAHABI MM, Ketentzi S, Kahraman U, Erdem HA, et al
    A single center's 25-year experience with hepatitis B and pneumoccocal vaccines in heart transplant patients: the impact of the COVID-19 pandemic.
    Vaccine. 2025;70:128023.
    

    >> Share

    
    
26. HUANG F, Deng Z, Huang Y, Lv Q, et al
    COVID-19 as a catalyst? Uptake and drivers of seasonal influenza and pneumococcal vaccination among older adults in post-pandemic Shenzhen, China.
    Vaccine. 2025;69:128013.
    

    >> Share

    
    
27. SPEDICATO M, Profeta F, Li Y, Celani P, et al
    Vaccine candidate based on a baculovirus expressed VP2 provides full protection from epizootic hemorrhagic disease virus serotype 8 in calves.
    Vaccine. 2025;69:128000.
    

    >> Share

    
    
28. CHILVER M, Ahsani Z, Sullivan SG, Edwards J, et al
    Evaluating the role of self-collected home swab data in enhancing influenza vaccine effectiveness estimates in general practice.
    Vaccine. 2025;69:127994.
    

    >> Share

    
    
29. VANASSE LT, Safdar B, Self WH, Zhu Y, et al
    Comparison of immunization information systems, electronic medical records, and self-report to ascertain RSV vaccination status among US adults aged >/=60 years, 2023-2024.
    Vaccine. 2025;69:127946.
    

    >> Share

    
    
30. ULRICH AK, Bigalke L, Arpey M, Redepenning S, et al
    Funding the priorities of the influenza vaccines research and development roadmap: an evaluation of global investment.
    Vaccine. 2025;69:127967.
    

    >> Share

    
    
31. NJOH AA, Bolio A, Venczel L, Libwea JN, et al
    Key players and determinants improving human papillomavirus vaccination coverage in Cameroon: a cross-sectional nationwide health workers survey.
    Vaccine. 2025;69:128006.
    

    >> Share

    
    
32. BOONE AC, Gaghan C, Fares A, Browning M, et al
    Ability to accelerate innate and cell-mediated immune responses in meat-type chickens by in ovo vaccination with monovalent and bivalent Marek's disease vaccines.
    Vaccine. 2025;69:128001.
    

    >> Share

    
    
33. STOECKER C, Wang Y, Leidner AJ, Cho BH, et al
    Cost-effectiveness of age-based and risk-based use of the new 21-valent pneumococcal conjugate vaccine among U.S. adults.
    Vaccine. 2025;69:127940.
    

    >> Share

    
    
34. WAHEED DE, Bolio A, Burdier R, Guillaume D, et al
    Barriers to HPV vaccine introduction and revitalization in sub-Saharan francophone African countries - A qualitative descriptive study.
    Vaccine. 2025;70:128030.
    

    >> Share

    
    
35. CHAVES SS, Castells VB, Wague S, Tian Z, et al
    Chlamydia vaccine willingness among young adults in Australia.
    Vaccine. 2025;70:128027.
    

    >> Share

    
    
36. SHAHEEN MNF, Clark A, Zaghlol A, Rashed MK, et al
    An impact and cost-effectiveness analysis of rotavirus vaccine introduction in Egypt.
    Vaccine. 2025;69:128010.
    

    >> Share

    
    
37. KELLY SA, Changalucha J, Malibwa D, Ewing VL, et al
    Knowledge and acceptability of male HPV vaccination among young people and community stakeholders in northwest Tanzania: social sciences in the Add-Vacc trial.
    Vaccine. 2025;69:128002.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share